期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 17, 页码 -出版社
MDPI
DOI: 10.3390/ijms23179935
关键词
atopic dermatitis (AD); B-type natriuretic peptide (BNP); chronic pruritus (CP); interleukin-31 (IL-31); oncostatin M (OSM); protease-activated receptor 2 (PAR2); T helper 2 (T(H)2); transient receptor potential vanilloid-3 (TRPV3); thymic stromal lymphopoietin (TSLP); Mas-related G-protein-coupled receptors (Mrgprs)
资金
- Henan University
- Sanofi Genzyme
- LEO Foundation
Chronic itch is a prominent clinical characteristic of various systematic diseases, but there are currently no specific FDA-labelled drugs for its treatment. The complex pathogenesis and diverse causes of chronic itch make it a major challenge in healthcare. However, newly identified potential itch targets have opened up new avenues for therapeutic development. This review aims to analyze the physiology and pathophysiology of different itch mediators, assess their suitability as new targets, and discuss future therapeutic development.
Chronic itch is one of the most prominent clinical characteristics of diverse systematic diseases. It is a devastating sensation in pathological diseases. Despite its importance, there are no FDA-labelled drugs specifically geared toward chronic itch. The associated complex pathogenesis and diverse causes escalate chronic itch to being one of the top challenges in healthcare. Humanized antibodies against IL-13, IL-4, and IL-31 proved effective in treatment of itch-associated atopic dermatitis but remain to be validated in chronic itch. There are still no satisfactory anti-itch therapeutics available toward itch-related neuropeptides including GRP, BNP, SST, CGRP, and SP. The newly identified potential itch targets including OSM, NMB, glutamate, periostin, and Serpin E1 have opened new avenues for therapeutic development. Proof-of-principle studies have been successfully performed on antagonists against these proteins and their receptors in itch treatment in animal models. Their translational interventions in humans need to be evaluated. It is of great importance to summarize and compare the newly emerging knowledge on chronic itch and its pathways to promote the development of novel anti-itch therapeutics. The goal of this review is to analyze the different physiologies and pathophysiologies of itch mediators, whilst assessing their suitability as new targets and discussing future therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据